What’s next in the fight against Ebola?
![](https://assets.weforum.org/article/image/large_u8q9IhldCpMF4O1IfLnyoyi5wUFvns8KKJxC-VvpUeI.jpg)
![A hand holding a looking glass by a lake](/uplink.jpg)
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:
Future of Global Health and Healthcare
When people look back on 2014, it may be best remembered as the year of Ebola. Two previous assumptions – that the virus was confined to remote regions of central Africa, and that the notorious virulence of the disease acted as a kind of self-limiting factor, with epidemics always burning themselves out after their initial flare-up – were shattered. Since its discovery in 1976, Ebola has been a curiosity in virology’s chamber of horrors, but in 2014 it well and truly arrived as a serious player in the global disease-threat league table.
As the world watched apprehensively and then stirred into action, the general impression was that the scientific and medical establishment had no suitable drugs, no vaccine and, some would have it, no clue. The truth, however, is a little more complicated.
Fast-tracked funding has led to a number of high-profile vaccine trials. While one Swiss trial was temporarily halted after a reported side effect of a rash, The Lancet reports that two experimental DNA vaccines to prevent Ebola (and the closely related Marburg virus), trialed for the first time in Africa, are safe. These filovirus vaccines generated an immune response in healthy Ugandan adults, as was previously reported in a US trial.
Tellingly, this latter phase 1 trial began enrolling people in Kampala between November 2009 and April 2010.
Slow speed?
The fact that previously the most westerly appearance of the Zaire variant of Ebola was nearly 5,000 kilometres away in Gabon and that one of the endemic viruses to pop up in Guinea every year is the similar but considerably less lethal Lassa fever, certainly contributed to the three-month lag between the first cases of Ebola and the official recognition of the outbreak.
But virologists have not been neglecting Ebola – in the 37 years since the virus was first identified, a large chest of potential treatments and vaccines have been developed, which were in various stages of progress when this year’s outbreak took hold. The fact that none of them had yet reached the stage of approval required for full commercial release, was more a consequence of the relatively small number of Ebola victims in a world where other viruses – HIV, hepatitis C, and influenza, to name the worst culprits – were killing millions, rather than any deliberate callousness on the part of pharmaceutical researchers and companies.
Nor were public health officials exactly fumbling around in the dark. Nearly four decades of dealing with smaller Ebola emergencies had produced a cadre of well-drilled outbreak response workers who knew exactly what steps to take to bring the virus under control. The only problem – and certainly a big one given the scale of this outbreak – was that these methods had previously only been tested in outbreaks numbering dozens, or at worst a couple of hundred cases, generally in well defined locations. Scaling these methods up to an outbreak area encompassing three countries was a task of unprecedented proportions.
Perhaps, after nearly nine months of struggle, the outbreak is finally coming under control, and governments and pharmaceutical companies will be much more prepared if there’s another epidemic in the future. The story is far from over, however. To reduce the outbreak to manageable levels is a triumph, but moving on to completely extinguishing the disease in West Africa may prove to be an equally gargantuan task. In the meantime, there is much we can, and must, learn to prevent a similar, or worse, recurrence in West Africa or elsewhere.
This article is published in collaboration with The Conversation. Publication does not imply endorsement of views by the World Economic Forum.
To keep up with Forum:Agenda subscribe to our weekly newsletter.
Author: Derek Gatherer is a lecturer at Lancaster University.
Image: Ward physician Thomas Klotzkowski and doctor for tropical medicine Florian Steiner (L) put on protective suits at the quarantine station for patients with infectious diseases at the Charite hospital in Berlin August 11, 2014. REUTERS/Thomas Peter.
Don't miss any update on this topic
Create a free account and access your personalized content collection with our latest publications and analyses.
License and Republishing
World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.
The views expressed in this article are those of the author alone and not the World Economic Forum.
Related topics:
The Agenda Weekly
A weekly update of the most important issues driving the global agenda
You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.
More on Geographies in DepthSee all
Sarah Rickwood, Sue Bailey and Daniel Mora-Brito
August 13, 2024
Mthuli Ncube
August 13, 2024
John Letzing
August 12, 2024
Mohamed Elshabik
August 9, 2024
Camilo Tellez-Merchan and Gisela Davico
August 7, 2024
Pamposh Raina
August 6, 2024